

1632/IFW

DOCKET NO.: C1040.70010US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: McCluskie et al.
Serial No.: 09/768,012
Confirmation No.: 9273
Filed: January 22, 2001
For: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR
INDUCING A TH2 IMMUNE RESPONSE
Examiner: Dave Trong Nguyen
Art Unit: 1632

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 25 day of October, 2004.


Kristin J. Ketelhut

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. §1.114.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Docket No.</u>	<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>
C1037.70013US01	10/831,778	April 23, 2004	Bratzler et al.
C1037.70039US01	10/816,220	April 1, 2004	McCluskie et al.
C1037.70048US00	10/644,052	August 19, 2003	Jurk et al.
C1037.70049US00	10/643,141	August 18, 2003	Hutcherson et al.
C1037.70052US00	10/668,050	September 22, 2003	Bratzler et al.
¹ C1039.70020US01	10/921,086	August 18, 2004	Krieg et al.
² C1039.70035US01	10/884,866	July 2, 2004	Krieg et al.
² C1039.70035US02	10/888,803	July 9, 2004	Krieg et al.
C1039.70048US02	10/817,165	April 2, 2004	Krieg et al.
³ C1039.70048US03	10/831,647	April 23, 2004	Krieg et al.
³ C1039.70048US04	10/847,642	May 15, 2004	Krieg et al.
³ C1039.70048US05	10/877,407	June 24, 2004	Krieg et al.
³ C1039.70048US06	10/884,852	July 2, 2004	Krieg et al.
³ C1039.70048US07	10/888,785	July 9, 2004	Krieg et al.
³ C1039.70048US08	10/888,449	July 9, 2004	Krieg et al.
³ C1039.70048US09	10/894,657	July 16, 2004	Krieg et al.
³ C1039.70048US10	10/894,862	July 16, 2004	Krieg et al.
³ C1039.70048US11	10/928,762	August 26, 2004	Krieg et al.
⁴ C1039.70057US01	10/838,659	May 3, 2004	Davis et al.

¹Copy not enclosed; see C1039.70020US00, Serial No. 09/337,584 for identical specification

²Copy not enclosed; see C1039.70035US00, Serial No. 09/699,187 for identical specification

³Copy not enclosed; see C1039.70048US02, Serial No. 10/817,165 for identical specification

⁴Copy not enclosed; see C1039.70057US00, Serial No. 09/965,101 for identical specification

Serial No.: 09/768,012
Conf. No.: 9273

- 3 -

Art Unit: 1632

<u>Docket No.</u>	<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>
C1039.70058US01	10/831,775	April 23, 2004	Davis et al.
C1039.70083US03	10/788,199	February 26, 2004	Krieg et al.
⁵ C1039.70083US08	10/847,650	May 15, 2004	Krieg et al.
⁵ C1039.70083US09	10/888,885	July 9, 2004	Krieg et al.
⁵ C1039.70083US10	10/888,089	July 9, 2004	Krieg et al.
C1039.70084US00	10/649,584	August 25, 2003	Krieg et al.
⁶ C1040.70006US01	10/888,886	July 9, 2004	McCluskie et al.
C1040.70012US00	10/644,267	August 20, 2003	Davis et al.
⁷ C1041.70002US01	10/877,369	June 25, 2004	Wagner et al.
⁷ C1041.70002US02	10/876,965	June 25, 2004	Wagner et al.
⁷ C1041.70002US03	10/876,892	June 25, 2004	Wagner et al.
⁸ C1041.70005US01	10/811,226	March 26, 2004	Wagner et al.
⁸ C1041.70005US02	10/894,655	July 16, 2004	Wagner et al.
C1041.70016US01	10/884,372	July 2, 2004	Bauer et al.
C1041.70024WO00	PCT/US04/12788	April 22, 2004	Vollmer et al.
C1041.70036US01	10/872,196	June 18, 2004	Lipford et al.
C1041.70040US00	10/666,844	September 19, 2003	Lipford et al.

⁵Copy not enclosed; see C1039.70083US03, Serial No. 10/788,199 for identical specification

⁶Copy not enclosed; see C1040.70006US00, Serial No. 09/316,199 for identical specification

⁷Copy not enclosed; see C1041.70002US00, Serial No. 09/241,653 for identical specification

⁸Copy not enclosed; see C1041.70005US00, Serial No. 09/355,254 for identical specification

The Applicant would like to bring to the Examiner's attention the enclosed search report from a corresponding International or Foreign National Application.

<u>Docket No.</u>	<u>Serial No.</u>	<u>Mailing Date</u>	<u>Type of Communication</u>
C1040.70010WO00	PCT/US01/02170	7 June 2001	International Search Report
C1040.70010WO00	PCT/US01/02170	13 September 2001	Written Opinion
C1040.70010WO00	PCT/US01/02170	18 January 2002	International Preliminary Examination Report

The following are remarks concerning the other information cited:

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Serial No.: 09/768,012
Conf. No.: 9273

- 5 -

Art Unit: 1632

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
McCluskie et al., Applicant

By:



Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: C1040.70010US00
Date: October 25, 2004
xNDDx



DOCKET NO.: C1040.70010US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: McCluskie et al.
Serial No.: 09/768,012
Confirmation No.: 9273
Filed: January 22, 2001
For: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING A TH2
IMMUNE RESPONSE
Examiner: Dave Trong Nguyen
Art Unit: 1632

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 25 day of October, 2004.


Kristin J. Ketelhut

MAIL STOP AMENDMENT

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.


Respectfully submitted,
McCluskie et al., Applicant

By:



Maria A. Trevisan, Reg. No.: 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: C1040.70010US00
Date: October 25 2004
xNDDx



INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/768,012		ATTY. DOCKET NO.: C1040.70010US00	
				FILING DATE: January 22, 2001		CONFIRMATION NO.: 9273	
				APPLICANT: McCluskie et al.			
				GROUP ART UNIT: 1632		EXAMINER: Dave Trong Nguyen	
Sheet	1	of	13				

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A44	6,653,292	B1	Krieg et al.	11-25-2003
	A45	6,727,230	B1	Hutcherson et al.	04-27-2004
	A46	2002-0064515	A1	Krieg et al.	05-30-2002
	A47	2002-0091097	A1	Bratzler et al.	07-11-2002
	A48	2002-0156033	A1	Bratzler et al.	10-24-2002
	A49	2002-0164341	A1	Davis et al.	11-07-2002
	A50	2002-0165178	A1	Schetter et al.	11-07-2002
	A51	2002-0198165	A1	Bratzler et al.	12-26-2002
	A52	2003-0026782	A1	Krieg et al.	02-06-2003
	A53	2003-0026801	A1	Weiner et al.	02-06-2003
	A54	2003-0050261	A1	Krieg et al.	03-13-2003
	A55	2003-0050263	A1	Krieg et al.	03-13-2003
	A56	2003-0050268	A1	Krieg et al.	03-13-2003
	A57	2003-0055014	A1	Bratzler	03-20-2003
	A58	2003-0087848	A1	Bratzler et al.	05-08-2003
	A59	2003-0091599	A1	Davis et al.	05-15-2003
	A60	2003-0100527	A1	Krieg et al.	05-29-2003
	A61	2003-0104523	A1	Bauer et al.	06-05-2003
	A62	2003-0139364	A1	Krieg et al.	07-24-2003
	A63	2003-0148316	A1	Lipford et al.	08-07-2003
	A64	2003-0148976	A1	Krieg et al.	08-07-2003
	A65	2003-0166001	A1	Lipford	09-04-2003
	A66	2003-0181406	A1	Schetter et al.	09-25-2003
	A67	2003-0191079	A1	Krieg et al.	10-09-2003
	A68	2003-0212026	A1	Krieg et al.	11-13-2003
	A69	2003-0224010	A1	Davis et al.	12-04-2003
	A70	2003-0232074	A1	Lipford et al.	12-18-2003
	A71	2004-0009949	A1	Krieg	01-15-2004
	A72	2004-0030118	A1	Wagner et al.	02-12-2004
	A73	2004-0053880	A1	Krieg	03-18-2004
	A74	2004-0067905	A1	Krieg	04-08-2004
	A75	2004-0087534	A1	Krieg et al.	05-06-2004
	A76	2004-0087538	A1	Krieg et al.	05-06-2004
	A77	2004-0092472	A1	Krieg	05-13-2004
	A78	2004-0106568	A1	Krieg et al.	06-03-2004
	A79	2004-0131628	A1	Bratzler et al.	07-08-2004
	A80	2004-0132685	A1	Krieg et al.	07-08-2004

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/768,012		ATTY. DOCKET NO.: C1040.70010US00	
				FILING DATE: January 22, 2001		CONFIRMATION NO.: 9273	
				APPLICANT: McCluskie et al.			
				GROUP ART UNIT: 1632		EXAMINER: Dave Trong Nguyen	
Sheet	2	of	13				

	A81	2004-0142469	A1	Krieg et al.	07-22-2004
	A82	2004-0143112	A1	Krieg et al.	07-22-2004
	A83	2004-0147468	A1	Krieg et al.	07-29-2004
	A84	2004-0152649	A1	Krieg	08-05-2004
	A85	2004-0152656	A1	Krieg et al.	08-05-2004
	A86	2004-0152657	A1	Krieg et al.	08-05-2004
	A87	2004-0162258	A1	Krieg et al.	08-19-2004
	A88	2004-0162262	A1	Krieg et al.	08-19-2004
	A89	2004-0167089	A1	Krieg et al.	08-26-2004
	A90	2004-0171150	A1	Krieg et al.	09-02-2004
	A91	2004-0171571	A1	Krieg et al.	09-02-2004
	A92	3,906,092		Hilleman et al.	09-16-1975
	A93	4,452,775		Kent	06-05-1984
	A94	4,544,559		Gil et al.	10-01-1985
	A95	4,994,442		Gil et al.	02-19-1991
	A96	5,023,243		Tullis	06-11-1991
	A97	5,066,500		Gil et al.	11-19-1991
	A98	5,075,109		Tice et al.	12-24-1991
	A99	5,087,617		Smith	02-11-1992
	A100	5,093,318		Goodman et al.	03-03-1992
	A101	5,248,670		Draper et al.	09-28-1993
	A102	5,457,189		Crooke et al.	10-10-1995
	A103	5,514,577		Draper et al.	05-07-1996
	A104	5,543,152		Webb et al.	08-06-1996
	A105	5,595,756		Bally et al.	01-21-1997
	A106	5,684,147		Agrawal et al.	11-04-1997
	A107	5,705,385		Bally et al.	01-06-1998
	A108	5,753,613		Ansell et al.	05-19-1998
	A109	5,756,097		Landucci et al.	05-26-1998
	A110	5,766,920		Babbitt et al.	06-16-1998
	A111	5,785,992		Ansell et al.	07-28-1998
	A112	5,814,335		Webb et al.	09-29-1998
	A113	5,837,243		Deo et al.	11-17-1998
	A114	5,932,556		Tam	08-03-1999
	A115	5,965,542		Wasan et al.	10-12-1999
	A116	5,976,567		Wheeler et al.	11-02-1999
	A117	5,981,501		Wheeler et al.	11-09-1999
	A118	6,004,534		Langer et al.	12-21-1999
	A119	6,027,726		Ansell	02-22-2000
	A120	6,030,955		Stein et al.	02-29-2000

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/768,012		ATTY. DOCKET NO.: C1040.70010US00	
				FILING DATE: January 22, 2001		CONFIRMATION NO.: 9273	
				APPLICANT: McCluskie et al.			
				GROUP ART UNIT: 1632		EXAMINER: Dave Trong Nguyen	
Sheet	3	of	13				

	A121	6,042,838		Briles et al.	03-28-2000
	A122	6,086,898		DeKruyff et al.	07-11-2000
	A123	6,110,745		Zhang et al.	08-29-2000
	A124	6,184,369	B1	Rando et al.	02-06-2001
	A125	6,191,257	B1	Ledley et al.	02-20-2001
	A126	6,225,292	B1	Raz et al.	05-01-2001
	A127	6,248,720	B1	Mathiowitz et al.	06-19-2001
	A128	6,498,147	B1	Nerenberg et al.	12-24-2002
	A129	6,498,148	B1	Raz	12-24-2002
	A130	6,503,533	B1	Korba et al.	01-07-2003
	A131	6,514,948	B1	Raz et al.	02-04-2003
	A132	6,534,062	B1	Raz et al.	03-18-2003
	A133	6,544,518	B1	Friede et al.	04-08-2003
	A134	6,552,006	B2	Raz et al.	04-22-2003
	A135	6,562,798	B1	Schwartz	05-13-2003
	A136	6,589,940	B1	Raz et al.	07-08-2003
	A137	6,610,661	B1	Carson et al.	08-26-2003
	A138	6,613,751	B1	Raz et al.	09-02-2003
	A139	6,737,066	B1	Moss	05-18-2004
	A140	2001-0034330	A1	Kensil	10-25-2001
	A141	2001-0036462	A1	Fong et al.	11-01-2001
	A142	2001-0041681	A1	Phillips et al.	11-15-2001
	A143	2001-0046967	A1	Van Nest et al.	11-29-2001
	A144	2002-0028784	A1	Van Nest et al.	03-07-2002
	A145	2002-0055477	A1	Van Nest et al.	05-09-2002
	A146	2002-0086839	A1	Raz et al.	07-04-2002
	A147	2002-0098199	A1	Van Nest et al.	07-25-2002
	A148	2002-0107212	A1	Van Nest et al.	08-08-2002
	A149	2002-0142978	A1	Raz et al.	10-03-2002
	A150	2003-0022852	A1	Van Nest et al.	01-30-2003
	A151	2003-0059773	A1	Van Nest et al.	03-27-2003
	A152	2003-0072762	A1	Van de Winkel et al.	04-17-2003
	A153	2002-0078223	A1	Baldonado et al.	06-20-2002
	A154	2003-0104044	A1	Semple et al.	06-05-2003
	A155	2003-0119773	A1	Raz et al.	06-26-2003
	A156	2003-0119774	A1	Foldvari et al.	06-26-2003
	A157	2003-0125279	A1	Junghans et al.	07-03-2003
	A158	2003-0125284	A1	Raz et al.	07-03-2003
	A159	2003-0125292	A1	Semple et al.	07-03-2003
	A160	2003-0129251	A1	Itakura et al.	09-12-2002

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/768,012		ATTY. DOCKET NO.: C1040.70010US00	
				FILING DATE: January 22, 2001		CONFIRMATION NO.: 9273	
				APPLICANT: McCluskie et al.			
				GROUP ART UNIT: 1632		EXAMINER: Dave Trong Nguyen	
Sheet	4	of	13				

	A161	2003-0133988	A1	Fearon et al.	07-17-2003
	A162	2003-0138413	A1	Vicari et al.	07-24-2003
	A163	2003-0143213	A1	Raz et al.	07-31-2003
	A164	2003-0147870	A1	Raz et al.	08-07-2003
	A165	2003-0165478	A1	Sokoll et al.	09-04-2003
	A166	2003-0175731	A1	Fearon et al.	09-18-2003
	A167	2003-0176373	A1	Raz et al.	09-18-2003
	A168	2003-0186921	A1	Carson et al.	10-02-2003
	A169	2003-0199466	A1	Fearon et al.	10-23-2003
	A170	2003-0212028	A1	Raz et al.	11-13-2003
	A171	2003-0216340	A1	Van Nest et al.	11-20-2003
	A172	2004-0006010	A1	Carson et al.	01-08-2004
	A173	2004-0006034	A1	Raz et al.	01-08-2004
	A174	2004-0009942	A1	Van Nest et al.	01-15-2004
	A175	2004-0064064	A1	Zhou et al.	04-01-2004
	A176	2004-0092468	A1	Schwartz et al.	05-13-2004

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B50	WO	2004/007743	A2	Coley Pharmaceutical GMBH	01-22-2004	
	B51	WO	2004/039829	A2	Coley Pharmaceutical Group, Ltd.	05-13-2004	
	B52	WO	93/15207	A2	Viagene Inc.	08-05-1993	
	B53	WO	95/17507	A1	Biagnostik Gesellschaft Für Biomolekulare Diagnostik MBH [DE]	06-29-1995	
	B54	WO	96/02560	A1	University of North Carolina at Chapel	02-01-1996	
	B55	WO	96/40162	A1	East Carolina University	12-19-1996	
	B56	WO	97/12633	A1	Immunex Corporation	04-10-1997	
	B57	WO	97/42975	A2	Genemedicine Inc.	11-20-1997	
	B58	WO	98/01538	A1	Immunex Corporation	01-15-1998	
	B59	WO	98/40100	A1	Ottawa Civic Loeb Research Institute	09-17-1998	
	B60	WO	98/49288	A1	Hybridon Inc.	11-05-1998	
	B61	WO	99/30686	A1	INEX Pharmaceuticals Corporation	06-24-1999	
	B62	WO	99/33488	A2	Smithkline Beecham Biologicals S.A.	07-08-1999	
	B63	WO	99/33493	A1	INEX Pharmaceuticals Corporation	07-08-1999	
	B64	WO	99/43350	A1	IOMAI Corporation	09-02-1999	
	B65	WO	99/52549	A1	Smithkline Beecham Biologicals S.A.	10-29-1999	
	B66	WO	00/15256	A2	Pasteur Merieux Serums Et Vaccins [FR]	03-23-2000	Y- Abstract Only
	B67	WO	00/21556	A1	Dynavax Technologies Corporation	04-20-2000	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/768,012		ATTY. DOCKET NO.: C1040.70010US00	
				FILING DATE: January 22, 2001		CONFIRMATION NO.: 9273	
				APPLICANT: McCluskie et al.			
				GROUP ART UNIT: 1632		EXAMINER: Dave Trong Nguyen	
Sheet	5	of	13				

	B68	WO	00/54803	A2	Panacea Pharmaceuticals, LLC.	09-21-2000	
	B69	WO	00/75304	A1	Aventis Pasteur [FR]	12-14-2000	Y- Abstract Only
	B70	WO	01/55341	A2	The Regents of the University of California	08-02-2001	
	B71	WO	01/62909	A1	Aventis Pasteur [FR]	08-30-2001	Y- Abstract Only
	B72	WO	01/68077	A2	Dynavax Technologies Corporation	09-20-2001	
	B73	WO	01/68078	A2	Dynavax Technologies Corporation	09-20-2001	
	B74	WO	01/68103	A2	Dynavax Technologies Corporation	09-20-2001	
	B75	WO	01/68116	A2	Dynavax Technologies Corporation	09-20-2001	
	B76	WO	01/68117	A2	Dynavax Technologies Corporation	09-20-2001	
	B77	WO	01/68143	A2	Dynavax Technologies Corporation	09-20-2001	
	B78	WO	01/68144	A2	Dynavax Technologies Corporation	09-20-2001	
	B79	WO	02/09748	A1	Yale University	02-07-2002	
	B80	WO	02/102307	A2	Ribapharm	12-27-2002	
	B81	WO	02/24225	A1	Glaxo Group Limited [GR]	03-28-2002	
	B82	WO	02/28428	A2	Aventis Pasteur [FR]	04-11-2002	Y- Abstract Only
	B83	WO	03/020889	A2	3M Innovative Properties Company	03-13-2003	
	B84	WO	03/024481	A2	Cytos Biotechnology AG	03-27-2003	
	B85	WO	03/030656	A2	Qiagen GMBH [DE]	04-17-2003	
	B86	WO	03/030934	A2	Qiagen GMBH [DE]	04-17-2003	
	B87	WO	03/045428	A2	Medigene Aktiengesellschaft	06-05-2003	Y- Abstract Only
	B88	WO	03/094963	A2	INEX Pharmaceuticals Corp.	11-20-2003	
	B89	WO	03/100040	A1	Merck Patent GMBH	12-04-2003	
	B90	WO	03/101375	A2	Immunotech SA	12-11-2003	
	B91	WO	2004/041183	A2	The Regents of the University of California	05-21-2004	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C128	ALPAR et al., Potential of particulate carriers for the mucosal delivery of DNA vaccines. Biochem Soc Trans. 1997 May;25(2):337S.	
	C129	ANDERSON et al., "Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides", <i>Cancer Immunology Immunotherapy</i> , 49(9): 459-68, 2000.	
	C130	ANDERSON et al., "TH2 and 'TH2-like' cells in allergy and asthma: pharmacological perspectives", <i>Trends in Pharmacological Science</i> , 15: 324-332, 1994.	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/768,012		ATTY. DOCKET NO.: C1040.70010US00	
				FILING DATE: January 22, 2001		CONFIRMATION NO.: 9273	
				APPLICANT: McCluskie et al.			
				GROUP ART UNIT: 1632		EXAMINER: Dave Trong Nguyen	
Sheet	6	of	13				

	C131	ARKWRIGHT et al., Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. <i>J Allergy Clin Immunol.</i> 2001 Mar;107(3):531-4.		
	C132	ASKEW et al., "CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms", <i>Journal of Immunology</i> , 165: 6889-95, 2000.		
	C133	BAUER et al., DNA activates human immune cells through a CpG sequence-dependent manner. <i>Immunology.</i> 1999 Aug;97(4):699-705.		
	C134	BAUER et al., Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. <i>J Immunol.</i> 2001 Apr 15;166(8):5000-7.		
	C135	BAYEVER et al., "Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial", <i>Antisense Research & Development</i> , 3: 383-390, 1993.		
	C136	BOWERSOCK et al., Evaluation of an orally administered vaccine, using hydrogels containing bacterial exotoxins of <i>Pasteurella haemolytica</i> , in cattle. <i>Am J Vet Res.</i> 1994 Apr;55(4):502-9.		
	C137	BRANDA et al., "Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1", <i>Biochemical Pharmacology</i> , 45(10): 2037-2043, 1993.		
	C138	BRAZOLOT-MILLAN et al., "CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice", <i>Proceedings of the National Academy of Science USA</i> , 95: 15553-15558, 1998.		
	C139	BROIDE et al., "DNA-Based immunization for asthma", <i>International Archives of Allergy and Immunology</i> , 118: 453-456, 1999.		
	C140	BROSSART et al., "Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells", <i>Blood</i> , 96(9): 3102-8, 2000.		
	C141	BRUNNER et al., "Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo", <i>Journal of Immunology</i> , 165: 6278-6286, 2000.		
	C142	CALAROTA et al., Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. <i>Lancet.</i> 1998 May 2;351(9112):1320-5.		
	C143	CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. <i>J Exp Med.</i> 1997 Nov 17;186(10):1621-2.		
	C144	CAVACINI et al., "Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen", <i>Clinical Cancer Research</i> , 8(2): 368-73, 2002.		
	C145	CELLA et al., Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. <i>Nat Med.</i> 1999 Aug;5(8):919-23.		
	C146	CHELVARAJAN et al., CpG oligodeoxynucleotides overcome the unresponsiveness of neonatal B cells to stimulation with the thymus-independent stimuli anti-IgM and TNP-Ficoll. <i>Eur J Immunol.</i> 1999 Sep;29(9):2808-18.		
	C147	CHEN et al., Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. <i>J Virol.</i> 1998 Jul;72(7):5757-61.		
	C148	CHOI et al., "The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant", <i>Vaccine</i> , 20(13-14): 1733-40, 2002.		
	C149	COHEN, Selective anti-gene therapy for cancer: principles and prospects. <i>Tohoku J Exp Med.</i> 1992 Oct;168(2):351-9.		
	C150	COSSUM et al., Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. <i>J Pharmacol Exp Ther.</i> 1993 Dec;267(3):1181-90.		
	C151	COWSERT et al., "In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts", <i>Antimicrobial Agents in Chemotherapy</i> , 37: 171-77, 1993.		
	C152	DALPKE et al., Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. <i>Immunology.</i> 2002 May;106(1):102-12.		
	C153	DAVIS et al., "CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen", <i>Journal of Immunology</i> , 160(2): 870-6, 1998.		
	C154	DAVIS et al., "CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans", <i>Vaccine</i> , 18: 1920-1924, 2000.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/768,012		ATTY. DOCKET NO.: C1040.70010US00	
				FILING DATE: January 22, 2001		CONFIRMATION NO.: 9273	
				APPLICANT: McCluskie et al.			
				GROUP ART UNIT: 1632		EXAMINER: Dave Trong Nguyen	
Sheet	7	of	13				

	C155	DAVIS et al., "Plasmid DNA expression systems for the purpose of immunization", <i>Current Opinions Biotechnology</i> , 8(5): 635-46, 1997.		
	C156	DAVIS et al., "Use of CpG DNA for enhancing specific immune responses", <i>Current Topics in Microbiology Immunology</i> , 247: 171-83, 2000.		
	C157	DEML et al., "Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins", <i>Clinical Chemistry Laboratory Medicine</i> , 37: 199-204 1999.		
	C158	DISIS et al., "Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine", <i>Clinical Cancer Research</i> , 5(6): 1289-97, 1999.		
	C159	DISIS et al., "Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines", <i>Journal of Clinical Oncology</i> , 20(11): 2624-32, 2002.		
	C160	DUMAIS et al., "Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge", <i>Journal of Infection and Disease</i> , 186(8): 1098-105, 2002.		
	C161	DUNN et al., The three Es of cancer immunoediting. <i>Annu Rev Immunol.</i> 2004;22:329-60.		
	C162	ELKINS et al., "Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria", <i>Journal of Immunology</i> , 162: 2291-2298, 1999.		
	C163	EL-SHAMI et al., "MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope", <i>European Journal of Immunology</i> , 29(10): 3295-301, 2002.		
	C164	FREIDAG et al., "CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis", <i>Infection and Immunity</i> , 68: 2948-2953, 2000.		
	C165	GALLICHAN et al., "Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract", <i>The Journal of Immunology</i> , 166: 3451-3457, 2001.		
	C166	GOUTTEFANGEAS et al., Problem solving for tumor immunotherapy. <i>Nat Biotechnol.</i> 2000 May;18(5):491-2.		
	C167	HARTMANN et al., "CpG DNA and LPS induce distinct patterns of activation in human monocytes", <i>Gene Therapy</i> , 6: 893-903, 1999.		
	C168	HARTMANN et al., "Mechanism and function of a newly identified CpG DNA motif in human primary B cells", <i>Journal of Immunology</i> , 164: 944, 2000.		
	C169	HARTMANN et al., "CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells", <i>Proceedings of the National Academy of Science USA</i> , 96: 9305-9310, 1999.		
	C170	HASLETT et al., Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. <i>J Infect Dis.</i> 2000 Apr;181(4):1264-72. Epub 2000 Apr 05.		
	C171	HAVLIR et al., Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. <i>N Engl J Med.</i> 1998 Oct 29;339(18):1261-8.		
	C172	HAYASHI et al., "Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase", <i>Infection and Immunity</i> , 69: 6156-6164, 2001.		
	C173	HECKELSMILLER et al., Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. <i>J Immunol.</i> 2002 Oct 1;169(7):3892-9.		
	C174	HEDLEY et al., Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. <i>Nat Med.</i> 1998 Mar;4(3):365-8.		
	C175	HEEG et al., CpG DNA as a Th1 trigger. <i>Int Arch Allergy Immunol.</i> 2000 Feb;121(2):87-97.		
	C176	HENRY et al., Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. <i>J Pharmacol Exp Ther.</i> 2000 Feb;292(2):468-79.		
	C177	HIGAKI et al., Mechanisms involved in the inhibition of growth of a human B lymphoma cell line, B104, by anti-MHC class II antibodies. <i>Immunol Cell Biol.</i> 1994 Jun;72(3):205-14.		
	C178	HINKULA et al., "Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes", <i>Journal of Virology</i> , 71(7): 5528-39, 1997.		
	C179	HO, Toward HIV eradication or remission: the tasks ahead. <i>Science.</i> 1998 Jun 19;280(5371):1866-7.		
	C180	HOHLWEG et al., On the fate of plant or other foreign genes upon the uptake in food or after intramuscular injection in mice. <i>Mol Genet Genomics.</i> 2001 Apr;265(2):225-33.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/768,012		ATTY. DOCKET NO.: C1040.70010US00	
				FILING DATE: January 22, 2001		CONFIRMATION NO.: 9273	
				APPLICANT: McCluskie et al.			
				GROUP ART UNIT: 1632		EXAMINER: Dave Trong Nguyen	
Sheet	8	of	13				

	C181	HOLMGREN et al., Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. <i>Vaccine</i> . 1993 Sep;11(12):1179-84.		
	C182	HOPKIN et al., BioMedNet, Issue 57, 6/25/1999.		
	C183	HORNER et al., Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. <i>J Allergy Clin Immunol</i> . 2002 Sep;110(3):413-20.		
	C184	HORNQUIST et al., Cholera toxin adjuvant greatly promotes antigen priming of T cells. <i>Eur J Immunol</i> . 1993 Sep;23(9):2136-43.		
	C185	HUNG et al., "Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen", <i>Journal of Immunology</i> , 166(9): 5733-40, 2001.		
	C186	IHO et al., "Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production in vitro", <i>Journal of Immunology</i> , 163: 3642, 1999.		
	C187	JAHRSDORFER et al., CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. <i>J Leukoc Biol</i> . 2001 Jan;69(1):81-8.		
	C188	JAKOB et al., "Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA", <i>Journal of Immunology</i> , 161(6): 3042-9, 1998.		
	C189	JAKOB et al., "Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses", <i>International Archives of Allergy Immunology</i> , 118(2-4): 457-61, 1999.		
	C190	JONES et al., Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. <i>Vaccine</i> . 1997 Jun;15(8):814-7.		
	C191	JONES et al., "Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys", <i>Vaccine</i> , 17: 3065-3071, 1999.		
	C192	JUFFERMANS et al., "CpG oligodeoxynucleotides enhance host defense during murine tuberculosis", <i>Infection and Immunity</i> , 70: 147-152, 2002.		
	C193	KANDIMALLA et al., "A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif", <i>Proceedings of the National Academy of Science</i> , 100(24): 14303-14308, 2003.		
	C194	KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. <i>Drug News Perspect</i> . 2000 Jun;13(5):289-96.		
	C195	KLINMAN et al., "Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection", <i>Infection and Immunity</i> , 67: 5658-5663, 1999.		
	C196	KLINMAN et al., "Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety", <i>Springer Seminars in Immunopathology</i> , 22: 173-183, 2000.		
	C197	KLINMAN et al., "Immune recognition of foreign DNA: a cure for bioterrorism?", <i>Immunity</i> , 11: 123-129, 1999.		
	C198	KLINMAN et al., "Contribution of CpG motifs to the immunogenicity of DNA vaccines", <i>Journal of Immunology</i> , 158(8): 3635-9, 1997.		
	C199	KLINMAN et al., "CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma", <i>Proceedings of the National Academy of Science USA</i> , 93(7): 2879-83, 1996.		
	C200	KOVARIK et al., "Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens", <i>Immunology</i> , 102(1): 67-76, 2001.		
	C201	KOVARIK et al., "CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming", <i>The Journal of Immunology</i> , 162: 1611-1617, 1999.		
	C202	KRANZER et al. "CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming", <i>Immunology</i> , 99: 170, 2000.		
	C203	KRIEG et al., "Immune effects and therapeutic applications of CpG motifs in bacterial DNA", <i>Immunopharmacology</i> , 48: 303-305, 2000.		
	C204	KRIEG et al., American College of Rheumatology 58th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. <i>Arthritis Rheum</i> . 1994 Sep;37(9 Suppl):116.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/768,012		ATTY. DOCKET NO.: C1040.70010US00	
				FILING DATE: January 22, 2001		CONFIRMATION NO.: 9273	
				APPLICANT: McCluskie et al.			
				GROUP ART UNIT: 1632		EXAMINER: Dave Trong Nguyen	
Sheet	9	of	13				

C205	KRIEG et al., "CpG DNA: a pathogenic factor in systemic lupus erythematosus?", <i>Journal of Clinical Immunology</i> , 15(6): 284-292, 1995.		
C206	KRIEG et al., "Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy", <i>Proceedings of the National Academy of Science</i> , 90: 1048-1052, 1993.		
C207	KRIEG et al., CpG motifs in bacterial DNA and their immune effects. <i>Annu Rev Immunol.</i> 2002;20:709-60. Epub 2001 Oct 04.		
C208	KRIEG et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. <i>Immunol Today.</i> 2000 Oct;21(10):521-6.		
C209	KRIEG et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation. <i>J Immunol.</i> 1989 Oct 15;143(8):2448-51.		
C210	KRIEG et al., 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996: p116.		
C211	KRIEG et al., "Enhancing vaccines with immune stimulatory CpG DNA", <i>Current Opinions Molecular Theory</i> , 3(1): 15-24, 2001.		
C212	KRIEG et al., Ernst Schering Research Found Workshop, (30): 105-18, 2001.		
C213	KRIEG et al., "Immune effects and mechanisms of action of CpG motifs", <i>Vaccine</i> , 19(6): 618-22, 2001.		
C214	KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. <i>Biochim Biophys Acta.</i> 1999 Dec 10;1489(1):107-16.		
C215	KRIEG et al., The CpG motif: Implications for clinical immunology. <i>BioDrugs.</i> 1998 Nov 1;10(5):341-6.		
C216	KRIEG et al., Immune stimulation by oligonucleotides. In <i>Antisense Research and Application</i> . S. T. Crooke, editor. Springer, Heidelberg. 1998: 471-515.		
C217	KRIEG et al. "The role of CpG motifs in innate immunity", <i>Current Opinions Immunology</i> , 12: 35, 2000.		
C218	KRIEG et al., "Mechanism of Action in CpG DNA", <i>Current Topics in Microbiology and Immunology</i> , 247: 1-21, 2000.		
C219	KRIEG et al., "Mechanisms and therapeutic applications of immune stimulatory cpG DNA", <i>Pharmacology & Therapeutics</i> , 84: 113, 1999.		
C220	KRIEG et al., "CpG DNA induces sustained IL-12 expression in vivo and resistance to <i>Listeria monocytogenes</i> challenge", <i>Journal of Immunology</i> , 161(5): 2428-2434, 1998.		
C221	KRIEG, Signal transduction induced by immunostimulatory CpG DNA. <i>Springer Semin Immunopathol.</i> 2000;22(1-2):97-105.		
C222	KRIEG, Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. <i>Trends Microbiol.</i> 1996 Feb;4(2):73-6.		
C223	KROWN et al., Phase I trial with the interferon inducer polyI/poly-I-lysine (Poly ICL). <i>Journal of Interferon Research</i> , 3: 281-90, 1983.		
C224	KRUG et al., Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. <i>Eur J Immunol.</i> 2001 Jul;31(7):2154-63.		
C225	KUKOWSKA-LATALLO et al., Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. <i>Proc Natl Acad Sci U S A.</i> 1996 May 14;93(10):4897-902.		
C226	KURAMOTO et al., "Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction", <i>International Immunopharmacology</i> , 14(5): 773-782, 1992.		
C227	LALLY et al., "Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading", <i>International Journal of Cancer</i> , 93(6): 841-7, 2001.		
C228	LEADBETTER et al., Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. <i>Nature.</i> 2002 Apr 11;416(6881):603-7.		
C229	LeCLERC et al., The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. <i>Cell Immunol.</i> 1997 Aug 1;179(2):97-106.		
C230	LIAU et al., "Tumor immunity within the central nervous system stimulated by recombinant <i>Listeria monocytogenes</i> vaccination", <i>Cancer Research</i> , 62(8): 2287-93, 2002.		
C231	LIPFORD et al., "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants", <i>European Journal of Immunology</i> , 27(9): 2340-4, 1997.		
C232	LIPFORD et al., "Bacterial DNA as immune cell activator", <i>Trends Microbiological</i> , 6(12): 496-500, 1998.		
C233	LIU et al., "Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor", <i>Blood</i> , 92(10): 3730-3736, 1998.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/768,012		ATTY. DOCKET NO.: C1040.70010US00	
				FILING DATE: January 22, 2001		CONFIRMATION NO.: 9273	
				APPLICANT: McCluskie et al.			
				GROUP ART UNIT: 1632		EXAMINER: Dave Trong Nguyen	
Sheet	10	of	13				

	C234	LOKE et al., "Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis", <i>Current Topics Microbiological Immunology</i> , 141: 282, 1988.		
	C235	MacGREGOR et al., First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. <i>J Infect Dis.</i> 1998 Jul;178(1):92-100.		
	C236	MALANCHERE-BRES et al., "CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice", <i>Journal of Virology</i> , 75(14): 6482-6491, 2001.		
	C237	MALTESE et al., "Sequence context of antisense RelA/NF-kappa B phosphorothioates determines specificity", <i>Nucleic Acids Research</i> , 23: 1146-51, 1995.		
	C238	MANZEL et al., "CpG-oligodeoxynucleotide-resistant variant of WEHI 231 cells", <i>Journal of Leukocyte Biology</i> , 66: 817, 1999.		
	C239	MARKIEWICZ et al., "Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A", <i>International Immunology</i> , 13(5): 625-32, 2001.		
	C240	MARTIN-OROZCO et al., Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. <i>Int Immunol.</i> 1999 Jul;11(7):1111-8.		
	C241	MATSON et al., "Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides", <i>Antisense Research and Development</i> , 2(4): 325-30, 1992.		
	C242	MATSUKURA et al., "Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells", <i>Proceedings of the National Academy of Science USA</i> , 86: 4244-48, 1989.		
	C243	MCCLUSKIE et al., "CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice", <i>Journal of Immunology</i> , 161: 4463-6, 1998.		
	C244	MCCLUSKIE et al., "Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants", <i>Vaccine</i> , 19: 413-422, 2001.		
	C245	MCCLUSKIE et al., Novel strategies using DNA for the induction of mucosal immunity. <i>Crit Rev Immunol.</i> 1999;19(4):303-29.		
	C246	MCCLUSKIE et al., Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. <i>Viral Immunol.</i> 1998;11(4):245-52.		
	C247	MCCLUSKIE et al., "CpG DNA is an effective oral adjuvant to protein antigens in mice", <i>Vaccine</i> , 19(7-8):950-7, 2000.		
	C248	MCCLUSKIE et al., "The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants", <i>Vaccine</i> , 19: 2657-2660, 2001.		
	C249	MCCLUSKIE et al., "The use of CpG DNA as a mucosal vaccine adjuvant", <i>Current Opinions Investigational Drugs</i> , 2(1): 35-9, 2001.		
	C250	MCCLUSKIE et al., "Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants", <i>Vaccine</i> , 19(27): 3759-68, 2001.		
	C251	MCCLUSKIE et al., "The potential of CpG oligodeoxynucleotides as mucosal adjuvants", <i>Critical Reviews in Immunology</i> , 21(1-3): 103-20, 2001.		
	C252	MCCLUSKIE et al., "Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA", <i>FEMS Immunology Medicine Microbiology</i> , 32(3): 179-85, 2002.		
	C253	MCCLUSKIE et al., "Mucosal immunization with DNA vaccines", <i>Microbes and Infection</i> , 1(9): 685-98, 1999.		
	C254	MCCLUSKIE et al., "Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution", <i>Molecular Medicine</i> , 6(10): 867-77, 2000.		
	C255	MCCLUSKIE et al., "The role of CpG in DNA vaccines", <i>Springer Seminars in Immunopathology</i> , 22(1-2): 125-32, 2000.		
	C256	MOJCIK et al., Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. <i>Clin Immunol Immunopathol.</i> 1993 May;67(2):130-6.		
	C257	MOLDOVEANU et al., "CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus", <i>Vaccine</i> , 16(11-12): 1216-1224, 1998.		
	C258	MONTEITH et al., Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents. <i>Anticancer Drug Des.</i> 1997 Jul;12(5):421-32.		
	C259	MOSS et al., In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides. <i>Vaccine.</i> 2000 Jan 6;18(11-12):1081-7.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/768,012		ATTY. DOCKET NO.: C1040.70010US00	
				FILING DATE: January 22, 2001		CONFIRMATION NO.: 9273	
				APPLICANT: McCluskie et al.			
				GROUP ART UNIT: 1632		EXAMINER: Dave Trong Nguyen	
Sheet	11	of	13				

	C260	MUI et al., Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. <i>J Pharmacol Exp Ther.</i> 2001 Sep;298(3):1185-92.		
	C261	OKADA et al., "Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms", <i>International Journal of Cancer</i> , 78(2): 196-201, 1998.		
	C262	PAL et al., "Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge", <i>Infection and Immunity</i> , 70(9): 4812-7, 2002.		
	C263	PARRONCHI et al., Phosphorothioate oligodeoxynucleotides promote the in vitro development of human allergen-specific CD4+ T cells into Th1 effectors. <i>J Immunol.</i> 1999 Dec 1;163(11):5946-53.		
	C264	PAYETTE et al., "History of vaccines and positioning of current trends", <i>Current Drugs Targets for Infection and Disorders</i> , 1(3): 241-7, 2001.		
	C265	PENG et al., CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice. <i>Int Immunol.</i> 2001 Jan;13(1):3-11.		
	C266	PERLAKY et al., Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression. <i>Anticancer Drug Des.</i> 1993 Feb;8(1):3-14.		
	C267	PINHAL-ENFIELD et al., An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors. <i>Am J Pathol.</i> 2003 Aug;163(2):711-21.		
	C268	PISETSKY et al., "The immunologic properties of DNA", <i>Journal of Immunology</i> , 156(2): 421-3, 1996.		
	C269	PISETSKY et al., Immunological properties of bacterial DNA. <i>Ann N Y Acad Sci.</i> 1995 Nov 27;772:152-63.		
	C270	PISETSKY et al., "Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus", <i>Life Sciences</i> , 54(2): 101-107, 1994.		
	C271	PISETSKY et al., Immune activation by bacterial DNA: a new genetic code. <i>Immunity.</i> 1996 Oct;5(4):303-10.		
	C272	PRASAD et al., "Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide", <i>Antimicrob Agents Chemother.</i> , 43(11):2689-96, 1999.		
	C273	RANIERI et al., "Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading", <i>Immunology Investigations</i> , 29(2): 121-5, 2000.		
	C274	RANKIN et al., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. <i>Antisense Nucleic Acid Drug Dev.</i> 2001 Oct;11(5):333-40.		
	C275	RANKIN et al., CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. <i>Vaccine.</i> 2002 Jul 26;20(23-24):3014-22.		
	C276	RATJCZAK et al., In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. <i>Proc Natl Acad Sci U S A.</i> 1992 Dec 15;89(24):11823-7.		
	C277	RAY et al., <i>Faseb J.</i> 2001; 15(5):A1007.		
	C278	RODGERS et al., Effects of acute administration of O,S,S-trimethyl phosphorodithioate on the generation of cellular and humoral immune responses following in vitro stimulation. <i>Toxicology.</i> 1988 Oct;51(2-3):241-53.		
	C279	RONNBLOM et al., A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. <i>J Exp Med.</i> 2001 Dec 17;194(12):F59-63.		
	C280	SAJIC et al., "Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge", <i>Journal of Medical Virology</i> , 71(4): 561-568, 2003.		
	C281	SANDLER et al., CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. <i>Cancer Res.</i> 2003 Jan 15;63(2):394-9.		
	C282	SCHWARTZ et al., Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. <i>J Immunol.</i> 1999 Jul 1;163(1):224-31.		
	C283	SEDEGAH et al., Interleukin 12 induction of interferon gamma-dependent protection against malaria. <i>Proc Natl Acad Sci U S A.</i> 1994 Oct 25;91(22):10700-2.		
	C284	SEGAL et al., Microbial products induce autoimmune disease by an IL-12-dependent pathway. <i>J Immunol.</i> 1997 Jun 1;158(11):5087-90.		
	C285	SETHI et al., "Postexposure prophylaxis against prion disease with a stimulator of innate immunity", <i>Lancet</i> , 360: 229-230, 2002.		
	C286	SINGH et al., Advances in vaccine adjuvants. <i>Nat Biotechnol.</i> 1999 Nov;17(11):1075-81.		
	C287	SJOLANDER et al., Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. <i>Cell Immunol.</i> 1997 Apr 10;177(1):69-76.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/768,012		ATTY. DOCKET NO.: C1040.70010US00	
				FILING DATE: January 22, 2001		CONFIRMATION NO.: 9273	
				APPLICANT: McCluskie et al.			
				GROUP ART UNIT: 1632		EXAMINER: Dave Trong Nguyen	
Sheet	12	of	13				

	C288	STAATS et al., Mucosal immunity to infection with implications for vaccine development. <i>Curr Opin Immunol.</i> 1994 Aug;6(4):572-83.		
	C289	STACEY et al. "Immunostimulatory DNA as an adjuvant in vaccination against <i>Leishmania major</i> ", <i>Infection and Immunity</i> , 67: 3719-3726, 1999.		
	C290	STEIN et al., Antisense oligonucleotides as therapeutic agents--is the bullet really magical? <i>Science</i> . 1993 Aug 20;261(5124):1004-12.		
	C291	STEIN et al., Physicochemical properties of phosphorothioate oligodeoxynucleotides. <i>Nucleic Acids Res.</i> 1988 Apr 25;16(8):3209-21.		
	C292	SUN et al. "Type I interferon-mediated stimulation of T cells by CpG DNA", <i>Journal of Experimental Medicine</i> , 188: 2335, 1998.		
	C293	TACKET et al., Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. <i>Vaccine</i> . 1999 Jul 16;17(22):2826-9.		
	C294	TANAKA et al., An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion. <i>J Exp Med.</i> 1992 Feb 1;175(2):597-607.		
	C295	TOKUNAGA et al., "A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth", <i>Japan Journal of Cancer Research</i> , 79(6): 682-6, 1988.		
	C296	TORTORA et al., Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. <i>Clin Cancer Res.</i> 2000 Jun;6(6):2506-12.		
	C297	TRACEY et al., Immunopharmacology of infectious disease 1987: 279.		
	C298	UGEN et al., DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. <i>Vaccine</i> . 1998 Nov;16(19):1818-21.		
	C299	UHLMANN et al., Recent advances in the development of immunostimulatory oligonucleotides. <i>Curr Opin Drug Discov Devel.</i> 2003 Mar;6(2):204-17.		
	C300	VALLIN et al., Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. <i>J Immunol.</i> 1999 Dec 1;163(11):6306-13.		
	C301	VANDERLUGT et al., "Epitope spreading in immune-mediated diseases: implications for immunotherapy", <i>Nature Reviews in Immunology</i> , 2(2): 85-95, 2002.		
	C302	VOLLMER et al., Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. <i>Antisense Nucleic Acid Drug Dev.</i> 2002 Jun;12(3):165-75.		
	C303	VOLLMER et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. <i>Eur J Immunol.</i> 2004 Jan;34(1):251-62.		
	C304	VOLLMER et al., Oligodeoxynucleotides lacking CpG dinucleotides mediate TLR9-dependent Th2-biased immun stimulation. Manuscript.		
	C305	WAAG et al., "Injection of inactivated phase I <i>Coxiella burnetii</i> increases non-specific resistance to infection and stimulates lymphokine production in mice", <i>Annual New York Academy of Science</i> , 590: 203-214, 1990.		
	C306	WAGNER, Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. <i>Curr Opin Microbiol.</i> 2002 Feb;5(1):62-9.		
	C307	WALKER et al., <i>Proceedings of the National Academy of Science, USA</i> , 96: 6970-6975, 1999.		
	C308	WANG et al., Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. <i>Int Immunol.</i> 2003 Feb;15(2):223-31.		
	C309	WANG et al., Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. <i>Science</i> . 1998 Oct 16;282(5388):476-80.		
	C310	WARREN et al., "APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells", <i>Journal of Immunology</i> , 165: 6244, 2000.		
	C311	WEERATNA et al., "Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides", <i>Antisense & Nucleic Drug Development</i> , 8: 351-356, 1998.		
	C312	WEERATNA et al., "CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice", <i>Immunology Cell Biology</i> , 81(1): 59-62, 2003.		
	C313	WEERATNA et al., "CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice", <i>FEMS Immunology Medicine Microbiology</i> , 32(1): 65-71, 2001.		
	C314	WEERATNA et al., "CpG DNA induces stronger immune responses with less toxicity than other adjuvants", <i>Vaccine</i> , 18(17): 1755-62, 2000.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/768,012		ATTY. DOCKET NO.: C1040.70010US00	
				FILING DATE: January 22, 2001		CONFIRMATION NO.: 9273	
				APPLICANT: McCluskie et al.			
				GROUP ART UNIT: 1632		EXAMINER: Dave Trong Nguyen	
Sheet	13	of	13				

	C315	WEERATNA et al., "Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies", <i>FEMS Immunology Medicine Microbiology</i> , 30(3): 241-7, 2001.		
	C316	WEIGEL et al., Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. <i>Blood</i> . 2002 Dec 1;100(12):4169-76. Epub 2002 Aug 08.		
	C317	WEINER et al., "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization", <i>Proceedings of the National Academy of Science USA</i> , 94(20): 10833-7, 1997.		
	C318	WERNETTE et al., "CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation", <i>Veterinary Immunology and Immunopathology</i> , 84(3-4): 223-236, 2002.		
	C319	WOOLDRIDGE et al. <i>Proceedings of American Association for Cancer Research</i> , 37: 477, 1996.		
	C320	WOOLDRIDGE et al., "Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma", <i>Blood</i> , 89(8): 2994-2998, 1997.		
	C321	WU et al., "Receptor-mediated gene delivery and expression in vivo", <i>Journal of Biological Chemistry</i> , 263: 14621-14624, 1988.		
	C322	YAMAMOTO et al., "Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity", <i>Microbiological Immunology</i> , 38(10): 831-836, 1994.		
	C323	YAMAMOTO et al., "Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity", <i>Journal of Immunology</i> , 148(12): 4072-4076, 1992.		
	C324	YAMAMOTO et al., "[Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG]", <i>Kekkaku</i> , 69(9): 571-4, 1994.	Y – Abstract Only	
	C325	YAMAMOTO et al., "Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length", <i>Antisense Research and Development</i> , 4(2): 119-123, 1994.		
	C326	YAMAMOTO et al., "Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro", <i>Japan Journal of Cancer Research</i> , 85: 775-779, 1994.		
	C327	YI et al., "Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway", <i>Journal of Immunology</i> , 157: 5394-5402, 1996.		
	C328	YI et al., "IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides", <i>Journal of Immunology</i> , 156(2): 558-64, 1996.		
	C329	YI et al. "CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry", <i>Journal of Immunology</i> , 160: 5898, 1998.		
	C330	ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Oct;7(5):495-502.		
	C331	ZHENG et al., DNA containing CpG motifs induces angiogenesis. <i>Proc Natl Acad Sci U S A</i> . 2002 Jun 25;99(13):8944-9. Epub 2002 Jun 11.		
	C332	ZIMMERMANN et al., "CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis", <i>Journal of Immunology</i> , 160(8): 3627-3630 1998.		

EXAMINE R	DATE CONSIDERED
-----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]